Overview

Vortioxetine for Binge Eating Disorder

Status:
Completed

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Takeda

Treatments:

Vortioxetine